Kelly A. Trippe, MA: No relationships to disclose
Avery Jackson, MD, FAANS FACS: No relationships to disclose
Lead Nurse Planner:
Susan Randall, MSN, RN, FNP-BC: No relationships to disclose
Editors and content reviewers:
Angelo Licata, MD, PhD: No relationships to disclose
Carolyn J. Bolognese, RN, CDE: No relationships to disclose
Peggy Doheny, PhD, RN, CNS, ONC, FAAN: No relationships to disclose.
Jeri Nieves, PhD: No relationships to disclose
Mary Beth O’Connell, PharmD, BCPS: No relationships to disclose
Rick Pope, MPAS, PA-C, DFAAPA: Faculty: Abbvie, Takeda Consultant: Medac, Sanofi-Biosurgery
Carol Sedlak, PhD, RN, CNS, ONC, CNE, FAAN: No relationships to disclose
Robert Westergan, MD: No relationships to disclose
NOF Clinical Director:
Andrea Singer, MD , FACP, CCD: Amgen: Consultant; Speakers Bureau / Teaching Engagements; Advisory Board. Eli Lilly : Consultant; Speakers Bureau / Teaching Engagements; Advisory Board. Hologic, Inc: Consultant. Medtronic: Consultant. Merck: Consultant. Radius: Consultant; Advisory Board. UCB: Consultant
Strategies to reduce fracture risk must be based on a sound understanding of the cellular, molecular, and biomechanical mechanisms that underlie the increased risk of fractures with aging. Whereas low bone mineral density (BMD) is among the strongest risk factors for fracture, a growing body of evidence demonstrates the limitations of current screening criteria and BMD measurement in targeting those at risk with fracture prevention therapy. These observations have brought renewed attention to the broader array of factors that influence fracture risk, collectively called “bone quality” and the need for better tools to measure parameters that determine skeletal strength and resistance to fracture. This issue of "Osteoporosis: Clinical Updates" we will take a look at current research in the field of fracture prediction and bone quality assessment and discuss implications for osteoporosis patient care settings, and is uniquely suited for primary care practice.
Recognize patients at low risk for fracture despite osteopenia by BMD T-score.
Identify patients who may benefit from non-DXA bone strength assessment.
Explain the limitations of DXA to fully characterize bone fragility.
Select the appropriate osteoporosis prediction tool for individual patients.
Interpret and explain the significance of a patient’s trabecular bone score.
National Osteoporosis Foundation
251 18th Street South, Suite 630, Arlington, VA 22202 I [p] 1 (800) 231-4222 • [f] 1 (703) 414-3742
The National Osteoporosis Foundation is a qualified 501(c)(3) tax-exempt organization and all donations to the organization are
tax deductible to the full extent allowable by law. NOF’s tax ID number is 36-3350532.